Cargando…
Sutimlimab for the Treatment of Cold Agglutinin Disease
Cold agglutinin disease (CAD) is a rare autoimmune hemolytic anemia and a bone marrow clonal lymphoproliferative disorder. Hemolysis in CAD is complement-dependent and mediated by the classical activation pathway. Patients also frequently suffer from fatigue and cold-induced circulatory symptoms. Al...
Autor principal: | Berentsen, Sigbjørn |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10155901/ https://www.ncbi.nlm.nih.gov/pubmed/37153870 http://dx.doi.org/10.1097/HS9.0000000000000879 |
Ejemplares similares
-
Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial
por: Röth, Alexander, et al.
Publicado: (2022) -
Sustained hematologic remission after discontinuation of sutimlimab treatment in patients with cold agglutinin disease
por: Gelbenegger, Georg, et al.
Publicado: (2022) -
Cold agglutinin disease: current challenges and future prospects
por: Berentsen, Sigbjørn, et al.
Publicado: (2019) -
Complement C1s inhibition with sutimlimab results in durable response in cold agglutinin disease: CARDINAL study 1-year interim follow-up results
por: Röth, Alexander, et al.
Publicado: (2022) -
New Insights in the Pathogenesis and Therapy of Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia
por: Berentsen, Sigbjørn
Publicado: (2020)